Medical Device Network on MSN
JPM26: Zimmer Biomet reveals plans for largest patient campaign in its history
The patient campaign is part of an effort to take Zimmer from being a company in ‘remediation mode’ and regain market share ...
WARSAW, Ind., Nov. 14, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) ...
WARSAW, Ind., and ZURICH, Nov. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (ZBH), a global medical technology leader, today received the CE Mark for its Persona® Revision Knee System. This ...
May 2 (Reuters) - Medtech firm Zimmer Biomet Holdings (ZBH.N), opens new tab beat Wall Street estimates for first-quarter profit on Thursday, on the back of robust demand for its devices that are used ...
According to GlobalData analysis, the surgical robotic market was valued at $10.0bn in 2025 and is projected to reach sales ...
Wide-moat Zimmer Biomet delivered decent second-quarter performance that generally met the firm’s goal of reaching mid-single-digit top-line growth that can be maintained. With few surprises, we’re ...
On Wednesday, Zimmer Biomet Holdings, Inc (NYSE:ZBH) reported third-quarter adjusted EPS of $1.74, up from $1.65 a year ago, in line with the Street estimates. The orthopedic giant reported sales of ...
Zimmer Biomet (ZBH) received the CE Mark for its Persona Revision Knee System. This addition to the Persona family builds on Zimmer Biomet’s commitment to personalized solutions, providing surgeons ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback